SCHEMBL857937

SCHEMBL857937

COc1cccc(Cc2[c]ncnc2C)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ENPP1 P22413 1/20 0.46
MAPT P10636 1/20 0.45
HTT P42858 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
DHFR P00374 1/20 0.44
CHRM2 P08172 1/20 0.43
CHRM1 P11229 1/20 0.43
CHRM3 P20309 1/20 0.43
HTR1B P28222 1/20 0.43
IDH1 O75874 1/20 0.42
CMA1 P23946 1/20 0.42
TAAR1 Q96RJ0 3/20 0.42
IDO1 P14902 2/20 0.42
AGXT P21549 2/20 0.42
FGFR1 P11362 1/20 0.41
FGFR4 P22455 1/20 0.41
MAOB P27338 3/20 0.41
APP P05067 1/20 0.41
AOC3 Q16853 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL856631 0.82 ENPP1 (0.42) ENPP1MAPTTAAR1IDO1MAOB
SCHEMBL856177 0.82 ALDH1A1 (0.46) MAPTSMN1; SMN2CMA1IDO1APP
SCHEMBL856706 0.80 ENPP1 (0.44) ENPP1SMN1; SMN2IDH1TAAR1IDO1
SCHEMBL856574 0.80 ENPP1 (0.44) ENPP1MAPTTAAR1IDO1AGXT
SCHEMBL857899 0.77 HTR2A (0.42) TAAR1IDO1MAOB
SCHEMBL2099512 0.73 CHRM2 (0.66) CHRM2CHRM1CHRM3HTR1BCMA1
SCHEMBL856148 0.72 ADORA2A (0.33) HTTMAOB
SCHEMBL858102 0.72 IDO1 (0.40) MAPTCHRM2CHRM1IDH1TAAR1
SCHEMBL856174 0.72 SMN1; SMN2 (0.33) MAPTHTTSMN1; SMN2TAAR1IDO1
SCHEMBL857450 0.72 SMN1; SMN2 (0.56) ENPP1MAPTHTTSMN1; SMN2DHFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-04-17 US disclosed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
EP-2640366-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE Exelixis, Inc. (US) 2013-09-25 EP disclosed
WO-2012068096-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE EXELIXIS, INC. (US) 2012-05-24 WO disclosed
EP-2432779-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES Exelixis, Inc. (US) 2012-03-28 EP disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
WO-2010135524-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA ENPP1 3408/4885MAPT 1278/4885HTT 2079/4885
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA ENPP1 3831/4885MAPT 1136/4885HTT 2326/4885
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA ENPP1 3308/4885MAPT 1639/4885HTT 2454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.